Expressing the magnitude of adverse effects in case-control studies: "the number of patients needed to be treated for one additional patient to be harmed"

被引:59
作者
Bjerre, LM
LeLorier, J
机构
[1] CHU Montreal, Ctr Rech, Pharmacoepidemiol & Pharmacoecon Res Unit, Montreal, PQ H2W 1T8, Canada
[2] McGill Univ, Fac Med, Dept Epidemiol & Biostat, Montreal, PQ H3A 1A2, Canada
关键词
D O I
10.1136/bmj.320.7233.503
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Results of epidemiological studies need to be expressed in understandable terms if they are to be of practical use to clinicians and policy makers Case-control studies are often used to stud) adverse effects of treatment; odds ratios from these are used to express the magnitude of adverse effects, but ar-e not intuitively understandable estimates of risk A more understandable and informative means of expressing the risk of adverse events in case-control studies is "the number of patients needed to be treated for one additional patient to be harmed" This is calculated from the odds ratio and the unexposed event rate-that is, the rate of occurrence of the adverse event of interest in people not exposed to the treatment.
引用
收藏
页码:503 / 506
页数:4
相关论文
共 11 条
[1]   Appetite-suppressant drugs and the risk of primary pulmonary hypertension [J].
Abenhaim, L ;
Moride, Y ;
Brenot, F ;
Rich, S ;
Benichou, J ;
Kurz, X ;
Higenbottam, T ;
Oakley, C ;
Wouters, E ;
Aubier, M ;
Simonneau, G ;
Begaud, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (09) :609-616
[2]   Confidence intervals for the number needed to treat [J].
Altman, DG .
BRITISH MEDICAL JOURNAL, 1998, 317 (7168) :1309-1312
[3]  
[Anonymous], 1997, CAN MED ASSOC J, DOI DOI 10.1136/BMJ.313.7069.1410
[4]   THE ASSOCIATION OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS WITH UPPER GASTROINTESTINAL-TRACT BLEEDING [J].
CARSON, JL ;
STROM, BL ;
SOPER, KA ;
WEST, SL ;
MORSE, ML .
ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (01) :85-88
[5]  
FARLEY TMM, 1995, LANCET, V346, P1582
[6]   RISK OF IDIOPATHIC CARDIOVASCULAR DEATH AND NONFATAL VENOUS THROMBOEMBOLISM IN WOMEN USING ORAL-CONTRACEPTIVES WITH DIFFERING PROGESTAGEN COMPONENTS [J].
JICK, H ;
JICK, SS ;
GUREWICH, V ;
MYERS, MW ;
VASILAKIS, C .
LANCET, 1995, 346 (8990) :1589-1593
[7]   AN ASSESSMENT OF CLINICALLY USEFUL MEASURES OF THE CONSEQUENCES OF TREATMENT [J].
LAUPACIS, A ;
SACKETT, DL ;
ROBERTS, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (26) :1728-1733
[8]   RISK OF UPPER GASTROINTESTINAL-BLEEDING AND PERFORATION ASSOCIATED WITH INDIVIDUAL NONSTEROIDAL ANTIINFLAMMATORY DRUGS [J].
RODRIGUEZ, LAG ;
JICK, H .
LANCET, 1994, 343 (8900) :769-772
[9]  
Sackett D L., 1996, Evid Based Med, V1, P164, DOI [DOI 10.1136/EBM.1996.1.164, 10.1136/ebm.1996.1, DOI 10.1136/EBM.1996.1]
[10]  
Sackett DL., 1991, CLIN EPIDEMIOLOGY BA